Clinical trials: Advanced Malignant Solid Neoplasm
Advanced Solid Tumor
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
- Trial name
- NCT05429398
- Testing
- Linperlisib Tablet
- Volunteers
- 118 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Cancer, Metastatic Cancer
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm
- Trial name
- NCT05162443
- Testing
- adagrasib (MRTX849)
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and…
- Trial name
- NCT04649385
- Testing
- BGB-15025, Tislelizumab, Carboplatin
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 157 people
- Sponsor
- BeiGene
Solid Tumor
Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors…
- Trial name
- NCT07108140
- Testing
- Anti ALPP CAR-T cells treatment
- Where
- China
- Volunteers
- 5 people
- Sponsor
- TCRCure Biopharma Ltd.
Advanced Solid Tumor
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2 overexpressing/expressing solid…
- Trial name
- NCT06413615
- Testing
- FDA022-BB05
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Neoplasms, Malignant
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Primary Objective: To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting…
- Trial name
- NCT01193595
- Testing
- Ombrabulin (AVE8062), bevacizumab
- Where
- 4 sites in France, Italy and 1 more
- Volunteers
- 39 people
- Sponsor
- Sanofi
Advanced Solid Tumor
A Study YL201 in Patients With Selected Advanced Solid Tumors
This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors.
- Trial name
- NCT06057922
- Testing
- YL201 for Injection
- Where
- 52 sites in China
- Volunteers
- 990 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
Protocol YY-20394-003 is a phase I single arm, open label study. The primary objective is to assess the safety of YY-20394 in subjects with advanced solid tumor.
- Trial name
- NCT04049929
- Testing
- YY-20394
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumor
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.
- Trial name
- NCT07298772
- Testing
- SHR-4375 Injection
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
TR128 in Patients With Advanced Solid Tumors
This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with…
- Trial name
- NCT05751356
- Testing
- TR128
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Advanced Solid Tumor, Malignant Solid Tumor
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts.
- Trial name
- NCT04145622
- Testing
- Ifinatamab deruxtecan (I-DXd)
- Where
- 23 sites in United States, Japan
- Volunteers
- 247 people
- Sponsor
- Daiichi Sankyo
Solid Tumors
Kanitinib in Treating Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety , tolerability, pharmacokinetics of Kanitinib and determine the optimal dose in patients with recurrent or metastatic solid tumors.
- Trial name
- NCT02916095
- Testing
- Kanitinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
Solid Tumors
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
- Trial name
- NCT02881190
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 57 people
- Sponsor
- RemeGen Co., Ltd.
Advanced or Metastatic Solid Tumors
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus Sintilimab in Patients with Advanced Solid Tumor
- Trial name
- NCT04427774
- Testing
- Surufatinib plus Sintilimab
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumor
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
This is an open-label, single-center, single-arm, phase 0, microdose study in subjects with advanced solid tumors and radiographically confirmed metastases.
- Trial name
- NCT05908773
- Testing
- TTX-MC138-NODAGA-Cu64
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- TransCode Therapeutics
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Unresectable, Locally Advanced or Metastatic Solid Tumors
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.
- Trial name
- NCT06418061
- Testing
- IBI3005
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.